Tibidi Pharmaceutical Technology

Tibidi Pharmaceutical Technology is a clinical-stage biotechnology company based in Suzhou, China, specializing in the discovery of small molecule therapeutics for undruggable targets. The company leverages a proprietary Fragment-based Drug Discovery (FBDD) platform combined with high-throughput X-ray crystallography to target complex protein-protein interactions (PPIs). Its primary research focus is on the RAS/MAPK signaling pathway, with lead programs targeting SHP2 and SOS1 for the treatment of various solid tumors. Tibidi aims to provide innovative solutions for cancer and other diseases with significant unmet medical needs through its structure-based drug design expertise. The company is supported by leading venture capital firms and operates within the BioBAY industrial park.